Target type: biologicalprocess
Any process that modulates the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester. [GOC:BHF, GOC:dph, GOC:tb]
The regulation of phospholipid catabolic process involves a complex interplay of enzymes, signaling pathways, and cellular factors. It is essential for maintaining cellular membrane integrity, lipid homeostasis, and various signaling events. Here's a detailed description:
**1. Enzyme Activation and Inhibition:**
* **Phospholipases:** Key enzymes responsible for breaking down phospholipids into their constituent components. Different phospholipases (A1, A2, C, D) target specific bonds within the phospholipid molecule, leading to the release of fatty acids, glycerol, and other signaling molecules.
* **Regulation of Phospholipases:** Their activity is tightly controlled by various mechanisms:
* **Calcium:** Many phospholipases are activated by calcium ions, which play a crucial role in signaling pathways triggered by stimuli like hormones and growth factors.
* **Protein Kinases:** Phosphorylation of phospholipases by protein kinases can either activate or inhibit their activity. This allows for fine-tuning of phospholipid breakdown based on cellular needs.
* **Regulatory Proteins:** Specific proteins can bind to phospholipases and either enhance or suppress their activity.
* **Lipid Composition:** The composition of the phospholipid substrate itself can influence the activity of specific phospholipases.
**2. Signaling Pathways:**
* **Phosphoinositide Signaling:** Breakdown of specific phosphoinositides (e.g., PIP2) by phospholipase C generates diacylglycerol (DAG) and inositol trisphosphate (IP3). These second messengers play crucial roles in activating protein kinase C (PKC) and releasing calcium from intracellular stores, respectively. This pathway is involved in cell growth, differentiation, and various other cellular processes.
* **Sphingomyelin Signaling:** Hydrolysis of sphingomyelin by sphingomyelinase releases ceramide, a potent signaling molecule involved in apoptosis, cell growth, and stress responses.
* **Lysophospholipid Signaling:** Lysophospholipids, generated by phospholipases, act as signaling molecules involved in inflammation, immune responses, and cell migration.
**3. Cellular Context:**
* **Membrane Remodeling:** The breakdown of phospholipids contributes to membrane remodeling, enabling cells to adapt to changes in their environment or during cell growth and division.
* **Lipid Homeostasis:** Phospholipid catabolism plays a vital role in maintaining lipid homeostasis by balancing phospholipid synthesis and degradation.
* **Disease Processes:** Dysregulation of phospholipid catabolism is implicated in various diseases, including cardiovascular disease, neurodegenerative disorders, and cancer.
**4. Environmental Factors:**
* **Oxidative Stress:** Reactive oxygen species can damage phospholipids, leading to their breakdown and contributing to oxidative stress.
* **Toxins and Drugs:** Certain toxins and drugs can directly or indirectly affect phospholipase activity, impacting phospholipid catabolism.
**Conclusion:** The regulation of phospholipid catabolic process is a complex and crucial cellular process. It involves a delicate balance of enzyme activity, signaling pathways, and cellular factors, ensuring proper membrane function, lipid homeostasis, and cellular signaling. Disruptions in this process can contribute to various disease states.'
"
Protein | Definition | Taxonomy |
---|---|---|
Isocitrate dehydrogenase [NADP] cytoplasmic | An isocitrate dehydrogenase [NADP] cytoplasmic that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
ciclopirox | cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone | antibacterial agent; antiseborrheic | |
zuclomiphene | Zuclomiphene: The cis or (Z)-isomer of clomiphene. | stilbenoid | |
mangostin | alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities. mangostin: xanthone from rind of Garcinia mangostana Linn. fruit | aromatic ether; phenols; xanthones | antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite |
licochalcone a | licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer | chalcones | |
gamma-mangostin | gamma-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3, 6 and 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antitumour activity. | phenols; xanthones | antineoplastic agent; plant metabolite; protein kinase inhibitor |
beta-Mangostin | xanthones | ||
nsc-287088 | |||
SYC-435 | SYC-435 : A cyclic hydroxamic acid that is 1-hydroxypyridin-2(1H)-one in which the hydrogens at positions 4 and 6 are substituted by methyl and benzyl groups, respectively. It is a potent inhibitor of mutant isocitrate dehydrogenase 1 (Ki values of 190 nM against R132H mutant and 120 nM against R132C mutant). | benzenes; cyclic hydroxamic acid; pyridone | antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor |
agi-5198 | AGI-5198: inhibits isocitrate dehydrogenase 1; structure in first source | ||
agi-6780 | AGI-6780: inhibits isocitrate dehydrogenases 1 and 2; structure in first source | ||
ivosidenib | ivosidenib : A tertiary carboxamide resulting from the formal condensation of the carboxy group of (2S)-1-(4-cyanopyridin-2-yl)-5-oxopyrrolidine-2-carboxylic acid with the secondary amino group of (2S)-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-2-[(5-fluoropyridin-3-yl)amino]acetamide. It is approved by the FDA for the treatment of acute myeloid leukemia (AML) in patients with an isocitrate dehydrogenase-1 (IDH1) mutation. ivosidenib: an inhibitor of isocitrate dehydrogenase 1 (IDH1) for treatment of acute myeloid leukemia (AML) | cyanopyridine; monochlorobenzenes; organofluorine compound; pyrrolidin-2-ones; secondary carboxamide; tertiary carboxamide | antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor |
enasidenib | 1,3,5-triazines; aminopyridine; aromatic amine; organofluorine compound; secondary amino compound; tertiary alcohol | antineoplastic agent; EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor |